TouchNEUROLOGY was recently joined by Dr Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the approval of aducanumab for Alzheimer’s disease (AD). Aducanumab was granted accelerated approval on 7 June 7 2021, by the U.S. Food and Drug Administration (FDA).
Areas covered in this short interview video: include the clinical trial programme leading to the approval; the ongoing EMBARK study; why aducanumab has succeeded when so many other drugs have failed late stage clinical trials; some of the challenges and opportunities presented by this approval; and looking at what questions remain unanswered and what future studies are planned.
Dr Sabbagh is a board-certified Geriatric Neurologist and is the director of translational research at Cleveland Clinic Lou Ruvo Center for Brain Health. The interview is available to view, here: Marwan Sabbagh: Approval of Aducanumab for Alzheimer's Disease - touchNEUROLOGY
TouchNEUROLOGY also spoke with Professor James Galvin (University of Miami Miller School of Medicine, Florida, USA) about the approval of aducanumab for the treatment of AD, and asked him what this recent accelerated approval might mean for future potential treatments. Prof. Galvin is a Professor of Neurology and is the Founder and Director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine. His interview was published online on 21 September 2021:
James E Galvin, AAIC 2021: Aducanumab for the Treatment of Alzheimer’s Disease - touchNEUROLOGY
